3 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 3 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow TUDCA: new trials by email Literature Review of TUDCA trials Research Report on TUDCA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index tauroursodeoxycholic acid (TUDCA), Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development | Phase 2 | Not yet recruiting | Peking University First Hospital | 80 | 2026-04-02 | 2026-04-08 |
| Targeting Endoplasmic Reticulum Stress in Human Hypertension TUDCA, Placebo - Hypertension | Phase 1 / Phase 2 | Recruiting | University of North Texas Health Science Center | 70 | 2023-08-15 | 2025-03-28 |
| Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Tauroursodeoxycholic Acid, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Unknown | Humanitas Mirasole SpA | 337 | 2019-02-22 | 2023-07-10 |
| Effects of TUDCA on Endothelial Function in Type 2 DM Tauroursodeoxycholic acid - Diabetes Mellitus, Type 2, Insulin Response | Not applicable | Terminated | Boston University | 2 | 2018-04-02 | 2021-03-24 |
| Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes Tauroursodeoxycholic Acid (TUDCA), Sugar Pill (placebo) - Type 1 Diabetes | Phase 2 | Completed | Robin Goland, MD | 20 | 2015-08-01 | 2025-06-05 |
| Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC tauroursodeoxycholic, ursodeoxycholic acid - Cholestatic Liver Disease | Phase 3 | Completed | Beijing Trendful Kangjian Medical Information Consulting Limited Company | 199 | 2009-08-01 | 2014-03-24 |
| Effect of Endoplasmic Reticulum Stress on Metabolic Function tauroursodeoxycholic acid, placebo, sodium phenylbutyrate - Insulin Resistance, Diabetes | Not applicable | Completed | Washington University School of Medicine | 101 | 2008-02-01 | 2018-05-29 |
Diabetes Mellitus, Type 2 (2) · Amyotrophic Lateral Sclerosis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Hypertension (1) · Ichthyosis prematurity syndrome (1) · Insulin Resistance (1) · Obesity (1)
Beijing Trendful Kangjian Medical Information Consulting Limited Company (1) · Boston University (1) · Humanitas Mirasole SpA (1) · Peking University First Hospital (1) · Robin Goland, MD (1) · University of North Texas Health Science Center (1) · Washington University School of Medicine (1)
United States (4) · Belgium (1) · China (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Alberto Albanese, MD (1) · Cheng Wei Chen, Doctor (1) · Guang Feng Shi, Doctor (1) · Gui Qiang Wang, Doctor (1) · Guo Feng Chen, Doctor (1) · He Ping Hu, Doctor (1) · Hong Tang, Doctor (1) · Hui Ping Yan, Doctor (1) · Ji Dong Jia, Doctor (1) · Ji Fang Sheng, Doctor (1) · Ji Yao Wang, Doctor (1) · Jie Xu, Doctor (1) · Jin Lin Hou, Doctor (1) · Lai Wei, Doctor (1) · Li Ping Duan, Doctor (1)
PMID 20522594, PMID 34547326, PMID 38053196
2018 (1)